SCHEMBL3298737

SCHEMBL3298737

C#CCN[C@@H]1CCc2ccc(OC(=O)NC)cc21

nearest known ligand 0.78

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ACHE P22303 18/20 0.78
MAOA P21397 2/20 0.70
MAOB P27338 2/20 0.70
BCHE P06276 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300157 1.00 ACHE (0.78) ACHEMAOAMAOBBCHE
Hydrochloric Acid SCHEMBL3298733 0.99 ACHE (0.80) ACHEMAOAMAOBBCHE
SCHEMBL608571 0.91 ACHE (0.78) ACHEMAOAMAOBBCHE
SCHEMBL3300162 0.91 ACHE (0.65) ACHEMAOAMAOBBCHE
SCHEMBL608570 0.91 ACHE (0.78) ACHEMAOAMAOBBCHE
SCHEMBL610866 0.91 ACHE (0.78) ACHEMAOAMAOBBCHE
Hydrochloric Acid SCHEMBL3297540 0.90 ACHE (0.67) ACHEMAOAMAOBBCHE
SCHEMBL3298383 0.89 ACHE (0.98) ACHEMAOAMAOBBCHE
SCHEMBL5319130 0.89 ACHE (0.82) ACHEMAOAMAOBBCHE
SCHEMBL3298374 0.89 ACHE (0.98) ACHEMAOAMAOBBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007100583-A2 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2007-09-07 WO claimed
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2007-08-30 US claimed
US-8609719-B2 Propargylated aminoindans, processes for preparation, and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2013-12-17 US disclosed
US-20100093848-A1 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2010-04-15 US disclosed
US-20100093848-A1 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2010-04-15 US disclosed
US-20100093848-A1 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2010-04-15 US disclosed
US-7625946-B2 Propargylated aminoindans, processes for preparation, and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-12-01 US disclosed
US-7625946-B2 Propargylated aminoindans, processes for preparation, and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-12-01 US disclosed
US-7625946-B2 Propargylated aminoindans, processes for preparation, and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-12-01 US disclosed
WO-2007100583-A2 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2007-09-07 WO disclosed
WO-2007100583-A2 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2007-09-07 WO disclosed
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2007-08-30 US disclosed
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2007-08-30 US disclosed
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203232-A1 Propargylated aminoindans, processes for preparation, and uses thereof PRMT3, PRMT1, PNMT ACHE 76/4885MAOA 511/4885MAOB 510/4885
US-20100093848-A1 PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF DNPEP, PEPD, ACHE ACHE 3/4885MAOA 482/4885MAOB 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.